{
  "context": {
    "rules": [
      "Rule1: If CompanyX develops a cure for DiseaseAlpha, then DiseaseAlpha has a successful treatment.",
      "Rule2: Provided that ResearcherA publishes a paper in JournalScience, it is not the case that CompanyX experiences a setback in a clinical trial.",
      "Rule3: ResearcherB publishes a paper in JournalNature or ResearcherA publishes a paper in JournalScience.",
      "Rule4: Whenever ResearcherA discovers the mechanism of SubstanceGamma, ResearcherB does not publish a paper in JournalNature.",
      "Rule5: If DiseaseAlpha develops resistance to TreatmentBeta, it requires a new treatment.",
      "Rule6: Under the condition that CompanyX secures a patent for SubstanceGamma, DiseaseAlpha has a successful treatment.",
      "Rule7: If CompanyY licenses technology from CompanyX, then CompanyX shares intellectual property with CompanyY.",
      "Rule8: Provided that CompanyX protects its patent, it is not the case that CompanyX shares intellectual property with CompanyY.",
      "Rule9: If CompanyY develops a cure for DiseaseAlpha, then DiseaseAlpha has a successful treatment.",
      "Rule10: Whenever ResearcherA receives an award, ResearcherA does not receive recognition.",
      "Rule11: ResearcherA collaborates with ResearcherB or, if neither ResearcherA achieves a breakthrough nor DiseaseAlpha has a successful treatment, ResearcherA receives an award.",
      "Rule12: If InstituteM completes a study on SubstanceGamma, then DiseaseAlpha has a successful treatment.",
      "Rule13: Under the condition that InstituteN completes a study on SubstanceGamma, DiseaseAlpha has a successful treatment.",
      "Rule14: If InstituteM initiates a trial for DiseaseAlpha, then InstituteM completes a study on SubstanceGamma.",
      "Rule15: Provided that InstituteN initiates a trial for DiseaseAlpha, InstituteN completes a study on SubstanceGamma.",
      "Rule16: If InstituteM obtains ethics approval, then InstituteM initiates a trial for DiseaseAlpha.",
      "Rule17: InstituteM obtains ethics approval or InstituteN obtains ethics approval.",
      "Rule18: Either CompanyX conducts research on SubstanceGamma or CompanyY conducts research on SubstanceGamma.",
      "Rule19: Whenever ResearcherC violates protocol, InstituteM does not face ethical issues.",
      "Rule20: ResearcherC violates protocol or ResearcherD violates protocol.",
      "Rule21: If ResearcherD violates protocol, then InstituteM does not face ethical issues.",
      "Rule22: Provided that SubstanceGamma shows efficacy against DiseaseAlpha, it shows toxicity.",
      "Rule23: SubstanceGamma shows efficacy against DiseaseAlpha or CompanyX does not receive funding from GrantOne.",
      "Rule24: If SubstanceGamma shows toxicity, then it passes a safety test.",
      "Rule25: Under the condition that SubstanceGamma shows toxicity, it does not pass a safety test.",
      "Rule26: If CompanyX conducts preclinical studies on SubstanceGamma, then CompanyY receives funding from GrantOne.",
      "Rule27: Provided that CompanyY conducts preclinical studies on SubstanceGamma, CompanyX does not receive funding from GrantOne.",
      "Rule28: If CompanyY conducts research on SubstanceGamma, then CompanyY develops a cure for DiseaseAlpha.",
      "Rule29: CompanyX continues research or, if CompanyY halts development of SubstanceGamma, then CompanyX halts development of SubstanceGamma.",
      "Rule30: CompanyY continues research or CompanyX does not continue research.",
      "Rule31: If CompanyZ withdraws its application from the FDA, then CompanyZ does not receive approval from the FDA.",
      "Rule32: CompanyX receives funding from GrantOne or, if CompanyX conducts research on SubstanceGamma, then CompanyX develops a cure for DiseaseAlpha.",
      "Rule33: Provided that CompanyW withdraws its application from the FDA, CompanyZ does not receive approval from the FDA.",
      "Rule34: If CompanyZ faces regulatory hurdles, then CompanyZ withdraws its application from the FDA.",
      "Rule35: CompanyZ faces regulatory hurdles or CompanyW faces regulatory hurdles.",
      "Rule36: If CompanyW faces regulatory hurdles, then CompanyZ encounters compliance issues.",
      "Rule37: Whenever CompanyZ encounters compliance issues, CompanyW encounters compliance issues.",
      "Rule38: Provided that CompanyW encounters compliance issues, CompanyW withdraws its application from the FDA.",
      "Rule39: If CompanyY challenges CompanyX's patent, then CompanyY does not license technology from CompanyX.",
      "Rule40: CompanyY challenges CompanyX's patent or CompanyZ challenges CompanyX's patent.",
      "Rule41: If CompanyY appeals the decision, then, if it is not the case that CompanyZ challenging CompanyX's patent implies that CompanyY does not license technology from CompanyX, then CompanyX wins a lawsuit.",
      "Rule42: If CompanyZ appeals the decision, then, provided that it is not the case that CompanyZ challenging CompanyX's patent implies that CompanyY does not license technology from CompanyX, then CompanyX wins a lawsuit.",
      "Rule43: Under the condition that CompanyZ applies for GrantOne, CompanyY receives funding from GrantOne or CompanyX does not receive funding from GrantOne.",
      "Rule44: CompanyZ receives approval from the FDA or CompanyZ applies for GrantOne.",
      "Rule45: CompanyZ submits an application to the FDA or CompanyZ does not receive approval from the FDA.",
      "Rule46: Provided that it is not the case that either CompanyX develops a cure for DiseaseAlpha or CompanyY develops a cure for DiseaseAlpha, CompanyY forms a consortium with CompanyX.",
      "Rule47: If it is not the case that either CompanyX develops a cure for DiseaseAlpha or CompanyY develops a cure for DiseaseAlpha, then CompanyX does not form a consortium with CompanyY.",
      "Rule48: Under the condition that it is not the case that either ResearcherA achieves a breakthrough or DiseaseAlpha has a successful treatment, ResearcherA receives recognition.",
      "Rule49: If it is not the case that InstituteN obtaining ethics approval implies that InstituteN initiates a trial for DiseaseAlpha, then InstituteM faces ethical issues.",
      "Rule50: If it is not the case that either CompanyX conducts preclinical studies on SubstanceGamma or CompanyY conducts preclinical studies on SubstanceGamma, then CompanyY halts development of SubstanceGamma.",
      "Rule51: Provided that it is not the case that CompanyY forming a consortium with CompanyX implies that CompanyX forms a consortium with CompanyY, CompanyX dissolves its partnership with CompanyY.",
      "Rule52: If it is not the case that CompanyY forming a consortium with CompanyX implies that CompanyX forms a consortium with CompanyY, then CompanyY dissolves its partnership with CompanyX.",
      "Rule53: Provided that it is not the case that CompanyY dissolving its partnership with CompanyX implies that CompanyX does not dissolve its partnership with CompanyY, CompanyX does not seek mediation with CompanyY.",
      "Rule54: Under the condition that it is not the case that CompanyZ challenging CompanyX's patent implies that CompanyY does not license technology from CompanyX, CompanyY loses a lawsuit.",
      "Rule55: Provided that it is not the case that either CompanyY appeals the decision or CompanyZ appeals the decision, CompanyY accepts the ruling.",
      "Rule56: If it is not the case that either CompanyY appeals the decision or CompanyZ appeals the decision, then CompanyY does not accept the ruling.",
      "Rule57: Under the condition that it is not the case that CompanyY dissolving its partnership with CompanyX not implying that CompanyX does not dissolve its partnership with CompanyY implies that CompanyX seeks mediation with CompanyY, CompanyX and CompanyY reach a settlement.",
      "Rule58: Under the condition that it is not the case that CompanyZ challenging CompanyX's patent not implying that CompanyY does not license technology from CompanyX implies that CompanyY does not lose a lawsuit, CompanyX does not win a lawsuit.",
      "Rule59: If it is not the case that CompanyY dissolving its partnership with CompanyX not implying that CompanyX does not dissolve its partnership with CompanyY not implying that CompanyX seeks mediation with CompanyY implies that CompanyX and CompanyY do not reach a settlement, then CompanyX renews collaboration with CompanyY.",
      "Rule60: If ResearcherA does not discover the mechanism of SubstanceGamma, then DiseaseAlpha develops resistance to TreatmentBeta.",
      "Rule61: Under the condition that CompanyX does not secure a patent for SubstanceGamma, CompanyY licenses technology from CompanyX.",
      "Rule62: Provided that DiseaseAlpha does not have a successful treatment, CompanyX experiences a setback in a clinical trial."
    ],
    "facts": [
      "Fact1: CompanyX protects its patent.",
      "Fact2: DiseaseAlpha does not require a new treatment.",
      "Fact3: ResearcherA does not achieve a breakthrough.",
      "Fact4: ResearcherA does not collaborate with ResearcherB.",
      "Fact5: CompanyX does not halt development of SubstanceGamma.",
      "Fact6: CompanyY does not continue research.",
      "Fact7: CompanyX does not renew collaboration with CompanyY.",
      "Fact8: CompanyY does not receive funding from GrantOne.",
      "Fact9: CompanyZ does not submit an application to the FDA."
    ]
  },
  "question": "DiseaseAlpha has a successful treatment."
}